Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


Articles published in Urol Int

Retrieve available abstracts of 39 articles:
HTML format
Text format



Single Articles


    March 2019
  1. CARRION A, Diaz F, Raventos C, Lozano F, et al
    Comparison of Outcomes between Standard and Palliative Management for High Grade Non-Muscle Invasive Bladder Cancer in Patients Older than 85 Years.
    Urol Int. 2019 Mar 7:1-7. doi: 10.1159/000496802.
    PubMed     Text format     Abstract available


    January 2019
  2. GROEBEN C, Koch R, Baunacke M, Borkowetz A, et al
    In-Hospital Outcomes after Radical Cystectomy for Bladder Cancer: Comparing National Trends in the United States and Germany from 2006 to 2014.
    Urol Int. 2019 Jan 30:1-9. doi: 10.1159/000496347.
    PubMed     Text format     Abstract available


  3. MOSCHINI M, Zamboni S, Mattei A, Baumeister P, et al
    Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?
    Urol Int. 2019 Jan 29:1-8. doi: 10.1159/000493899.
    PubMed     Text format     Abstract available


    November 2018
  4. SANGUEDOLCE F, Russo D, Mancini V, Selvaggio O, et al
    Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review.
    Urol Int. 2018 Nov 21:1-13. doi: 10.1159/000494359.
    PubMed     Text format     Abstract available


  5. LAUSENMEYER EM, Braun K, Breyer J, Gierth M, et al
    Strong Expression of Cancertestis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer.
    Urol Int. 2018 Nov 1:1-6. doi: 10.1159/000493577.
    PubMed     Text format     Abstract available


    September 2018
  6. BOSSCHIETER J, Nieuwenhuijzen JA, Hentschel A, Vis AN, et al
    Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial.
    Urol Int. 2018 Sep 28:1-8. doi: 10.1159/000493159.
    PubMed     Text format     Abstract available


  7. KRAJEWSKI W, Zdrojowy R, Dembowski J, Poletajew S, et al
    The Optimal Timing of Restaging Resection before Introduction of Bacillus Calmette-Guerin Immunotherapy in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
    Urol Int. 2018 Sep 28:1-9. doi: 10.1159/000491642.
    PubMed     Text format     Abstract available


  8. VETTERLEIN MW, Gild P, Marks P, Roschinski J, et al
    Evaluating Guideline Adherence for T1 Bladder Cancer Treatment and Surveillance: A Retrospective German Multicenter Observation.
    Urol Int. 2018 Sep 20:1-8. doi: 10.1159/000493369.
    PubMed     Text format     Abstract available


  9. KRAJEWSKI W, Matuszewski M, Poletajew S, Grzegrzolka J, et al
    Are There Differences in Toxicity and Efficacy between Various Bacillus Calmette-Guerin Strains in Bladder Cancer Patients? Analysis of 844 Patients.
    Urol Int. 2018 Sep 18:1-8. doi: 10.1159/000492722.
    PubMed     Text format     Abstract available


    August 2018
  10. MARI A, D'Andrea D, Kimura S, Resch I, et al
    Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer.
    Urol Int. 2018;101:1-4.
    PubMed     Text format     Abstract available


    May 2018
  11. DRAEGER DL, Sievert KD, Hakenberg OW
    Psychosocial Distress in Bladder Cancer Stratified by Gender, Age, Treatment, and Tumour Stage.
    Urol Int. 2018 May 14:1-7. doi: 10.1159/000489502.
    PubMed     Text format     Abstract available


    March 2018
  12. CERRUTO MA, D'Elia C, Siracusano S, Saleh O, et al
    Health-Related Quality of Life after Radical Cystectomy for Bladder Cancer in Elderly Patients with Ileal Orthotopic Neobladder or Ileal Conduit: Results from a Multicentre Cross-Sectional Study Using Validated Questionnaires.
    Urol Int. 2018 Mar 7. pii: 000487644. doi: 10.1159/000487644.
    PubMed     Text format     Abstract available


  13. DOGAN S, Hennig M, Frank T, Struck JP, et al
    Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice.
    Urol Int. 2018 Mar 6. pii: 000487405. doi: 10.1159/000487405.
    PubMed     Text format     Abstract available


    January 2018
  14. ZUCCHI A, Costantini E
    "Nested Type" Bladder Cancer: Myth or Reality?
    Urol Int. 2018 Jan 17. pii: 000486533. doi: 10.1159/000486533.
    PubMed     Text format    


  15. TAN P, Xie N, Yang L, Liu L, et al
    Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma Increased the Risk of Intravesical Recurrence.
    Urol Int. 2018;100:92-99.
    PubMed     Text format     Abstract available


  16. PALAZZETTI A, Bosio A, Dalmasso E, Destefanis P, et al
    De Novo Bladder Urothelial Neoplasm in Renal Transplant Recipients: A Retrospective, Multicentered Study.
    Urol Int. 2018;100:185-192.
    PubMed     Text format     Abstract available


  17. NIEGISCH G, Nini A, Michalski R, Henn A, et al
    Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion.
    Urol Int. 2018;101:224-231.
    PubMed     Text format     Abstract available


  18. GONZALEZ-PEREZ L, Alvarez-Arguelles H, Ramos Gutierrez VJ, Hernandez SG, et al
    Bladder Fetal Rhabdomyoma Intermediate Type.
    Urol Int. 2018;101:240-244.
    PubMed     Text format     Abstract available


  19. SANGUEDOLCE F, Landriscina M, Ambrosi A, Tartaglia N, et al
    Bladder Metastases from Breast Cancer: Managing the Unexpected. A Systematic Review.
    Urol Int. 2018;101:125-131.
    PubMed     Text format     Abstract available


  20. FERRO M, Vartolomei MD, Cantiello F, Lucarelli G, et al
    High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.
    Urol Int. 2018;101:7-15.
    PubMed     Text format     Abstract available


  21. BEN BAHRIA-SEDIKI I, Chebil M, Sampaio C, Martel-Frachet V, et al
    Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder.
    Urol Int. 2018;100:476-484.
    PubMed     Text format     Abstract available


  22. GIERTH M, Zeman F, Denzinger S, Vetterlein MW, et al
    Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study.
    Urol Int. 2018;101:16-24.
    PubMed     Text format     Abstract available


    December 2017
  23. ZATTONI F, Palumbo V, Giannarini G, Crestani A, et al
    Perioperative Outcomes and Early Survival in Octogenarians Who Underwent Radical Cystectomy for Bladder Cancer.
    Urol Int. 2017 Dec 7. pii: 000478990. doi: 10.1159/000478990.
    PubMed     Text format     Abstract available


    June 2017
  24. NAGAO K, Hara T, Nishijima J, Shimizu K, et al
    The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
    Urol Int. 2017 Jun 21. doi: 10.1159/000477912.
    PubMed     Text format     Abstract available


  25. POLETAJEW S, Zapala P, Radziszewski P
    Safety and Efficacy of Intravesical Bacillus Calmette-Guerin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.
    Urol Int. 2017 Jun 10. doi: 10.1159/000477673.
    PubMed     Text format     Abstract available


    April 2017
  26. BALCI M, Tuncel A, Keten T, Guzel O, et al
    Comparison of Monopolar and Bipolar Transurethral Resection of Non-Muscle Invasive Bladder Cancer.
    Urol Int. 2017 Apr 6. doi: 10.1159/000467397.
    PubMed     Text format     Abstract available


    March 2017
  27. NAKAMURA Y, Yoshida S, Tanaka H, Inoue M, et al
    Potential Utility of Diffusion-Weighted Magnetic Resonance Imaging in Diagnosis of Residual Bladder Cancer before Second Transurethral Resection.
    Urol Int. 2017 Mar 1. doi: 10.1159/000456722.
    PubMed     Text format     Abstract available


    February 2017
  28. MOSCHINI M, Shariat SF, Freschi M, Soria F, et al
    Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer.
    Urol Int. 2017 Feb 1. doi: 10.1159/000454736.
    PubMed     Text format     Abstract available


    January 2017
  29. LONG X, Qi L, Zu X, Li Y, et al
    Prevention of Recurrent Bladder Tumors after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: An Individualized Selection Strategy Based on Patient Risk Stratification Is Needed.
    Urol Int. 2017;98:312-319.
    PubMed     Text format     Abstract available


  30. WOLTERS M, Oelke M, Lutze B, Weingart M, et al
    Deep Surgical Site Infections after Open Radical Cystectomy and Urinary Diversion Significantly Increase Hospitalisation Time and Total Treatment Costs.
    Urol Int. 2017;98:268-273.
    PubMed     Text format     Abstract available


    December 2016
  31. BREYER J, Otto W, Wirtz RM, Wullich B, et al
    ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.
    Urol Int. 2016.
    PubMed     Text format     Abstract available


  32. D'ELIA C, Comploj E, Cerruto MA, Trenti E, et al
    90-Day Mortality after Radical Cystectomy for Bladder Cancer: Prognostic Factors in a Multicenter Case Series.
    Urol Int. 2016.
    PubMed     Text format     Abstract available


    January 2016
  33. SOORIAKUMARAN P, Chiocchia V, Dutton S, Pai A, et al
    Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients.
    Urol Int. 2016;96:83-90.
    PubMed     Text format     Abstract available


  34. SERRETTA V, Scalici Gesolfo C, Alonge V, Cicero G, et al
    Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?
    Urol Int. 2016;96:20-4.
    PubMed     Text format     Abstract available


  35. MARTINI T, Aziz A, Roghmann F, Rink M, et al
    Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter Study.
    Urol Int. 2016;96:57-64.
    PubMed     Text format     Abstract available


  36. MILLER K, Morant R, Stenzl A, Zuna I, et al
    A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transi
    Urol Int. 2016;96:5-13.
    PubMed     Text format     Abstract available


  37. TANAKA H, Yoshida S, Komai Y, Sakai Y, et al
    Clinical Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Upper Tract Urothelial Carcinoma: Impact on Detection of Metastases and Patient Management.
    Urol Int. 2016;96:65-72.
    PubMed     Text format     Abstract available


  38. GAKIS G, Efstathiou JA, Daneshmand S, Keegan KA, et al
    Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma.
    Urol Int. 2016;97:134-41.
    PubMed     Text format     Abstract available


  39. D''AGOSTINO D, Racioppi M, Pugliese D, Ragonese M, et al
    Postoperative Quality of Life in Patients with Ileal Neobladder at Short-, Intermediate- and Long-Term Follow-Up.
    Urol Int. 2016;97:54-60.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: